Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs has proposed a novel vaccine approach to enhance the efficacy of CAR-T in syngeneic solid tumor models by increasing the number and function of CAR-T with low toxicity. The bispecific vaccine CAR design with amph-FITC vaccine provides a simple and versatile solution to improve CAR-T for any antigen specificity.

Background

CAR-T immunotherapy targeting the CD19 antigen has produced some significant clinical responses in patients with leukemia and lymphoma, including a high proportion of durable complete responses. However, in some patients, poor functional persistence of CAR-T can lead to disease progression. Despite the success of CAR-T therapy in hematological cancers, it has so far been much less effective in solid tumors, and strategies to improve efficacy in this setting remain an important goal. Therapeutic vaccination is a well-established method to enhance endogenous T cell response to cancer. Some research groups have demonstrated the concept of preparing CAR-T from virus-specific endogenous lymphocytes, or introducing CAR with a secondary antigen receptor against the target peptide and then administering a viral or secondary antigen vaccine to facilitate CAR-T therapy. However, due to the limitations of HLA, it is necessary to develop other treatment strategies. Creative Biolabs offers a method to enhance CAR-T function through direct vaccination of chimeric receptors in solid tumors.

Fig.1 Diagram of an amphiphilic ligand vaccine design.¹

Our Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions

Creative Biolabs designed an amphipathic CAR-T ligand (Amphiphile-ligand) that, after injection, is transported to lymph nodes and decorates the surface of antigen-presenting cells, thereby initiating CAR-Ts in the native lymph node microenvironment. Amphiphile-ligand enhancement triggers massive CAR-T expansion, increases donor cell versatility, enhances multiple immune-competent mouse tumor models, and enhances anti-tumor efficacy. Creative Biolabs is scaling this technology strategy to any chimeric antigen receptor with two solutions that enable this simple non-human leukocyte antigen-restricted approach to enhance CAR-T function for application to existing CAR-T designs.

In Vitro CAR-T Cell Functional Analysis with Amphiphile-ligand Coated DC

As a leader in the field of hematological oncology, Creative Biolabs carries out in vitro CAR-T cell function analysis of amphiphilic ligand-coated DCs, providing customers with detection services for in vitro cellular immune function, number of CAR-T cells, cytokine levels, tumor burden and toxicity and side effects of CAR-T cell therapy.

In Vivo CAR-T Cell Functional Analysis after Amphi-ligand Vaccination

In vivo efficacy experiments are the most important indicators to evaluate the therapeutic activity of drugs, and the current important models for in vivo efficacy evaluations of drugs, including cell therapy products, are mainly based on heterologous tumor models constructed on severely immunodeficient mice. Creative Biolabs' one-stop CAR-T R&D platform provides different types of animal models and various index testing services for in vivo CAR-T cell function analysis after Amphi-ligand vaccination. In addition, Creative Biolabs also has rich experience in the construction of homologous mouse tumor models, and has established a rich tumor model database, which can provide customers with a full range of in vivo efficacy evaluation services.

These methods can be combined or customized to specific research questions and experimental requirements to achieve enhanced efficacy of CAR-T cell therapies in a variety of biological and disease contexts.

Our Advantage

Fig.2 Our advantages. (Creative Biolabs Original) Fig.2 Our advantages.

Combining amphiphilic molecules with ligand-based vaccines for boosting CAR-T cell therapies is an innovative approach with potential applications in cancer immunotherapy. Combining amphiphilic molecules with ligand-based vaccines for CAR-T cell therapy can enhance antigen presentation, enable targeted delivery, enable immunomodulation, and sustained antigen exposure. However, this approach is still in its infancy and requires extensive basic research to evaluate its safety and efficacy. In addition, the selection of ligands, amphiphilic carriers, and their formulations needs to be carefully optimized to maximize therapeutic efficacy. At this point, you can fully trust Creative Biolabs. Equipped with professional scientists and advanced technology platforms, we have been committed to providing perfect services to our customers. If you are interested in this Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions, please feel free to contact us. Our technicians will be happy to assist you.

Reference

Ma, Leyuan et al. "Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor." Science. 365,6449 (2019): 162-168.